ADIM
ARCB icon

Alpha DNA Investment Management’s ArcBest ARCB Stock Holding History

Alpha DNA Investment Management’s Portfolio ARCB Stock Details ARCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,949
Closed -$980K – 152
2022
Q2 		$980K Buy
+13,949
New +$1.03M 0.84% 66

Other funds holding ARCB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Alpha DNA Investment Management's ARCB Position: Q3 2022 in Review

Alpha DNA Investment Management sold out of ArcBest (ARCB) in Q3 2022, closing a stake of 13,949 shares — an estimated $980K sold.

Alpha DNA Investment Management first reported a position in ARCB in Q2 2022 and held it in 1 quarter. The position peaked at $980K in Q2 2022. 258 funds tracked by Wall St. Rank hold ARCB as of Q3 2022.

  • Alpha DNA Investment Management reported no remaining ArcBest position as of Q3 2022 after selling out during the quarter.
  • Alpha DNA Investment Management sold 13,949 ArcBest shares in Q3 2022, an estimated $980K.
  • Alpha DNA Investment Management first reported a position in ArcBest in Q2 2022 and held it in 1 quarter.
  • Alpha DNA Investment Management's ArcBest position peaked at $980K in Q2 2022.
  • 258 funds tracked by Wall St. Rank held ArcBest as of Q3 2022.

Based on Alpha DNA Investment Management's 13F filing for Q3 2022, filed 15 Nov 2022.